Woodline Partners LP Bluebird Bio, Inc. Transaction History

Woodline Partners LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$0.85 - $1.26 $4,952 - $7,340	-5,826 Reduced 0.6%	969,336 $949,000
Q1 2024 May 15, 2024	BUY	$0.91 - $1.75 $432,266 - $831,281	475,018 Added 94.98%	975,162 $1.25 Million
Q4 2023 Feb 14, 2024	SELL	$1.32 - $4.83 $2.94 Million - $10.8 Million	-2,228,593 Reduced 81.67%	500,144 $690,000
Q3 2023 Nov 14, 2023	BUY	$3.02 - $4.05 $5.88 Million - $7.88 Million	1,945,845 Added 248.55%	2,728,737 $8.3 Million
Q2 2023 Aug 14, 2023	SELL	$2.79 - $5.03 $14,042 - $25,315	-5,033 Reduced 0.64%	782,892 $2.58 Million
Q1 2023 May 15, 2023	SELL	$3.14 - $8.22 $1.58 Million - $4.13 Million	-502,774 Reduced 38.95%	787,925 $2.51 Million
Q4 2022 Feb 14, 2023	BUY	$5.77 - $8.49 $877,853 - $1.29 Million	152,141 Added 13.36%	1,290,699 $8.93 Million
Q3 2022 Nov 14, 2022	BUY	$3.75 - $7.39 $4.27 Million - $8.41 Million	1,138,558 New	1,138,558 $7.21 Million
Q3 2021 Nov 15, 2021	SELL	$11.24 - $21.0 $1.16 Million - $2.16 Million	-102,940 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$18.04 - $22.09 $1.23 Million - $1.51 Million	68,443 Added 198.4%	102,940 $3.29 Million
Q1 2021 May 17, 2021	BUY	$16.59 - $33.89 $572,305 - $1.17 Million	34,497 New	34,497 $1.04 Million

151

63.4M

264K

428K

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $28.5M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

Get notified when there are updates to the investment portfolio of Woodline Partners LP, based on Form 13F filings with the SEC.

Stay updated on Woodline Partners LP with notifications on news.